RT Journal Article
T1 Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
A1 Moreno, Victor
A1 Roda, Desamparados
A1 Pikiel, Joanna
A1 Trigo, Jose
A1 Bosch-Barrera, Joaquim
A1 Drew, Yvette
A1 Kristeleit, Rebecca
A1 Hiret, Sandrine
A1 Bajor, David L
A1 Cruz, Patricia
A1 Beck, J Thaddeus
A1 Ghosh, Srimoyee
A1 Dabrowski, Christine
A1 Antony, Grace
A1 Duan, Tao
A1 Veneris, Jennifer
A1 Zografos, Eleftherios
A1 Subramanian, Janakiraman
K1 Cancer immunity
K1 Immune checkpoint inhibitors
K1 Lung neoplasms
K1 PD-1
K1 Treatment outcome
AB Dostarlimab is an anti-programmed cell death protein-1 antibody being evaluated in recurrent/advanced solid tumors, including non-small cell lung cancer (NSCLC), in the ongoing Phase I, multi-center, open-label, 2-part (dose escalation and cohort expansion) GARNET study (NCT02715284). Here, we report an interim analysis of patients with recurrent/advanced NSCLC who progressed following platinum-based chemotherapy. Patients received dostarlimab (500 mg IV every 3 weeks [Q3W] for Cycles 1-4, then 1000 mg Q6W) until disease progression or unacceptable toxicity for > 2 years. The primary endpoints were immune-related objective response rate (irORR) per investigator-assessed irRECIST and safety. As of 8, July 2019, 67 patients with recurrent/advanced NSCLC were enrolled and treated with dostarlimab; the majority had programmed death ligand 1 (PD-L1) tumor proportion score (TPS)  Dostarlimab demonstrated promising antitumor activity in advanced/recurrent NSCLC that progressed following platinum-based chemotherapy, including across all PD-L1 subgroups, and has an acceptable safety profile.
PB Elsevier
YR 2022
FD 2022-05-19
LK http://hdl.handle.net/10668/22104
UL http://hdl.handle.net/10668/22104
LA en
NO Moreno V, Roda D, Pikiel J, Trigo J, Bosch-Barrera J, Drew Y, et al. Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial. Clin Lung Cancer. 2022 Nov;23(7):e415-e427
DS RISalud
RD Apr 9, 2025